Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velaglucerase alfa in pediatric Type 3 Gaucher Disease
NCT01685216Phase 2Completed
- Sponsor
- Takeda
- Start
- Sep 2012
- Primary completion
- Mar 2015
- Modality
- Replacement Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of velaglucerase alfa in Gaucher disease type 3, sponsored by Takeda. Started Sep 2012; status: completed.
02
Drugs
velaglucerase alfa
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on NCT01685216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01685216.